Optimizing CAR T cell therapy for solid tumours: a clinical perspective.
This review addresses the challenges of applying CAR T cell therapy in solid tumors, highlighting recent advancements ai...
Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment.
- Post category:Hematologic Cancers
- Reading time:1 min read
This review highlights the recent advances in antibody-drug conjugates (ADCs), noting their increasing clinical approval...
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST.
- Post category:Hematologic Cancers
- Reading time:1 min read
This study evaluates the real-world efficacy and safety of two CAR T-cell therapies, idecabtagene vicleucel (ide-cel) an...
Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion.
- Post category:Hematologic Cancers
- Reading time:1 min read
This study developed an allogeneic matched donor CD19 CAR product (CAR-DLI) for adult patients with B-cell acute lymphob...
Investigation of early mortality in the patients with newly diagnosed multiple myeloma: insights from a real-world cohort using J-CHAEGE-MM database.
- Post category:Hematologic Cancers
- Reading time:1 min read
This study analyzed early mortality in multiple myeloma using data from the J-CHARGE-MM database, identifying that nearl...
Interim analysis of a multicenter study on patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: the RODEO study.
- Post category:Hematologic Cancers
- Reading time:1 min read
This interim analysis from the RODEO study investigates patient-guided tyrosine kinase inhibitor (TKI) dose reduction in...